Taysha's Rett Syndrome Gene Therapy Hits Dual Milestones, Paving Regulatory Path Toward Potential Approval
Taysha Gene Therapies has dosed the first patient in its pivotal REVEAL trial for TSHA-102 and secured FDA agreement to incorporate data from its earlier ASPIRE study into a future marketing application, marking a significant step in its quest to bring a treatment for Rett syndrome to market.